Mixed lineage leukaemia-4 regulates cell-cycle progression and cell viability and its depletion suppresses growth of xenografted tumour in vivo

British Journal of Cancer

Volumn 107, Issue 2, 2012, Pages 315-324

  Ansari, K I ^a   Kasiri, S ^a   Mishra, B P ^a   Mandal, S S ^a  

^a UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

Author keywords

histone methylation; mixed lineage leukaemia; MLL antisense; MLL4; tumour suppression; tumour xenograft

Indexed keywords

CASPASE 3; CASPASE 7; CYCLIN D; CYCLIN E; CYTOCHROME C; MIXED LINEAGE LEUKEMIA 4 PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN P27; RNA POLYMERASE II; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA5; TRANSCRIPTION FACTOR HOXB7; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; GENE SILENCING; HISTONE METHYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL CYCLE; CELL CYCLE PROTEINS; CELL DEATH; CELL SURVIVAL; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HELA CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MICE; MICE, NUDE;

EID: 84863718882     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.263     Document Type: Article

References (33)

1. Ajiro K, Allis CD (2002) Histone code hypothesis. Tanpakushitsu Kakusan Koso 47: 753-760
2. Ansari KI, Grant JD, Woldemariam GA, Kasiri S, Mandal SS (2009) Iron(III)-salen complexes with less DNA cleavage activity exhibit more efficient apoptosis in MCF7 cells. Org Biomol Chem 7: 926-932
3. Ansari KI, Hussain I, Kasiri S, Mandal SS (2012) HOXC10 is overexpressed in breast cancer and transcriptionally regulated by estrogen via involvement of histone methylases MLL3 and MLL4. J Mol Endocrinol 48: 61-75
4. Ansari KI, Hussain I, Shrestha B, Kasiri S, Mandal SS (2011) HOXC6 Is transcriptionally regulated via coordination of MLL histone methylase and estrogen receptor in an estrogen environment. J Mol Biol 411: 334-349
5. Ansari KI, Mandal SS (2010) Mixed lineage leukemia: roles in gene expression, hormone signaling and mRNA processing. FEBS J 277: 1790-1804
6. Bannister AJ, Kouzarides T (2005) Reversing histone methylation. Nature 436: 1103-1106
7. Bhaumik SR, Smith E, Shilatifard A (2007) Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 14: 1008-1016
8. Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee JW, Verdine GL, Allis CD, Roeder RG (2006) Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol 13: 713-719
9. Dreijerink KM, Mulder KW, Winkler GS, Hoppener JW, Lips CJ, Timmers HT (2006) Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res 66: 4929-4935
10. Favaro E, Lord S, Harris AL, Buffa FM (2011) Gene expression and hypoxia in breast cancer. Genome Med 3: 55
11. Guenther MG, Jenner RG, Chevalier B, Nakamura T, Croce CM, Canaani E, Young RA (2005) Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci USA 102: 8603-8608
12. Hess JL (2004) MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med 10: 500-507
13. Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A (2011) Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. Onco Targets Ther 4: 149-168
14. Kouzarides T (2007) Chromatin modifications and their function. Cell 128: 693-705
15. Lee J, Kim DH, Lee S, Yang QH, Lee DK, Lee SK, Roeder RG, Lee JW (2009) A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci USA 106: 8513-8518
16. Lee J, Saha PK, Yang QH, Lee S, Park JY, Suh Y, Lee SK, Chan L, Roeder RG, Lee JW (2008a) Targeted inactivation of MLL3 histone H3-Lys-4 methyltransferase activity in the mouse reveals vital roles for MLL3 in adipogenesis. Proc Natl Acad Sci USA 105: 19229-19234
17. Lee S, Lee J, Lee SK, Lee JW (2008b) Activating signal cointegrator-2 is an essential adaptor to recruit histone H3 lysine 4 methyltransferases MLL3 and MLL4 to the liver X receptors. Mol Endocrinol 22: 1312-1319
18. Liao WT, Jiang D, Yuan J, Cui YM, Shi XW, Chen CM, Bian XW, Deng YJ, Ding YQ (2011) HOXB7 as a prognostic factor and mediator of colorectal cancer progression. Clin Cancer Res 17: 3569-3578
19. Marschalek R (2010) Mixed lineage leukemia: roles in human malignancies and potential therapy. FEBS J 277: 1822-1831
20. Mishra BP, Ansari KI, Mandal SS (2009) Dynamic association of MLL1, H3K4 trimethylation with chromatin and Hox gene expression during the cell cycle. FEBS J 276: 1629-1640
21. Mo R, Rao SM, Zhu YJ (2006) Identification of the MLL2 complex as a coactivator for estrogen receptor alpha. J Biol Chem 281: 15714-15720
22. Orrenius S, Gogvadze V, Zhivotovsky B (2007) Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol 47: 143-183
23. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, Gallia GL, Jallo GI, Binder ZA, Nikolsky Y, Hartigan J, Smith DR, Gerhard DS, Fults DW, VandenBerg S, Berger MS, Marie SK, Shinjo SM, Clara C, Phillips PC, Minturn JE, Biegel JA, Judkins AR, Resnick AC, Storm PB, Curran T, He Y, Rasheed BA, Friedman HS, Keir ST, McLendon R, Northcott PA, Taylor MD, Burger PC, Riggins GJ, Karchin R, Parmigiani G, Bigner DD, Yan H, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 331: 435-439
24. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera R (2011) Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 43: 830-837
25. Paulussen AD, Stegmann AP, Blok MJ, Tserpelis D, Posma-Velter C, Detisch Y, Smeets EE, Wagemans A, Schrander JJ, van den Boogaard MJ, van der Smagt J, van Haeringen A, Stolte-Dijkstra I, Kerstjens-Frederikse WS, Mancini GM, Wessels MW, Hennekam RC, Vreeburg M, Geraedts J, de Ravel T, Fryns JP, Smeets HJ, Devriendt K, Schrander-Stumpel CT (2010) MLL2 mutation spectrum in 45 patients with Kabuki syndrome. Hum Mutat 32: E2018-E2025
26. Poon RY, Toyoshima H, Hunter T (1995) Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol Biol Cell 6: 1197-1213
27. Roskoski Jr R (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62: 179-213
28. Singhal SS, Singhal J, Yadav S, Dwivedi S, Boor PJ, Awasthi YC, Awasthi S (2007) Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1). Cancer Res 67: 4382-4389
29. Stasinopoulos IA, Mironchik Y, Raman A, Wildes F, Winnard Jr P, Raman V (2005) HOXA5-twist interaction alters p53 homeostasis in breast cancer cells. J Biol Chem 280: 2294-2299
30. Tammali R, Ramana KV, Singhal SS, Awasthi S, Srivastava SK (2006) Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res 66: 9705-9713
31. Tan YC, Chow VT (2001) Novel human HALR (MLL3) gene encodes a protein homologous to ALR and to ALL-1 involved in leukemia, and maps to chromosome 7q36 associated with leukemia and developmental defects. Cancer Detect Prev 25: 454-469
32. Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, Zhang R (2002) Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol 21: 73-80
33. Wendt MK, Smith JA, Schiemann WP (2010) Transforming growth factorbeta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 29: 6485-6498